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Objectives: Venous thromboembolism (VTE) is a common complication for can-
cer patients, leading to hospitalizations that increase the cost of management of 
these patients. The objective of the present study was to evaluate the number and 
the cost of VTE-related hospitalizations for patients with breast or prostate cancer 
during the two first years of their oncologic treatment. MethOds: Patients with 
breast cancer (BC) or prostate cancer (PC) diagnosed in 2010 who had at least one 
VTE-related hospitalization during the following two years were selected from the 
French national hospital database (PMSI), using the disease-specific ICD-10 codes. 
Hospital costs were estimated from the third-party payer perspective using the 
official diagnosis related group (DRG) tariffs for each year considered. Results: In 
2010,62,365 patients newly diagnosed with BC and 45,551 with PC were admitted 
in French hospitals. Among them, 1,271 in the BC cohort (2.0%) and 997 in the PC 
cohort (2.2%) were hospitalized for VTE at least once during the two-year follow-
up, leading to 1,604 stays for BC patients and 1,210 stays for PC patients. During a 
2-years follow-up, 15.9% of BC patients and 14.4% of PC patients were re-hospitalized 
for VTE recurrence. The mean cost per stay was 3,261€ and 3,584€ for BC and PC 
respectively. Mean cost per patient was estimated at 3,302€ and 3,611€ for BC and 
PC patients hospitalized once for VTE-related events, and it increased to 5,545€ and 
5,692€ for BC and PC patients who presented recurrences. Over a 2-year period, total 
hospital cost induced by VTE-related events reached 1.98 million and 1.43 million € 
for BC and PC, respectively. cOnclusiOns: VTE-related hospitalizations in breast 
or prostate cancer patients lead to a significant economic burden that could be 
reduced by decreasing VTE recurrence.
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Objectives: To examine the economic burden and health care utilization of 
melanoma patients in the U. S. Medicare population. MethOds: A retrospec-
tive database analysis was performed using U. S. national Medicare claims from 
01JAN2008 to 31DEC2012. Melanoma patients were identified using International 
Classification of Disease 9thRevision Clinical Modification (ICD-9-CM) diagnosis 
code 172. xx. The first diagnosis date was designated as the index date. A compara-
tor group was created, consisting of patients with the same age, region, gender, 
index year, and matched baseline Charlson Comorbidity Index scores but with-
out a melanoma diagnosis. A random index date was chosen for the comparator 
cohort to reduce selection bias. Patients were required to have continuous medical 
and pharmacy benefits 1 year pre- and post-index date. One-to-one propensity 
score matching (PSM) was performed to compare follow-up health care costs and 
utilizations between the cohorts, adjusting for demographic and clinical charac-
teristics. Results: Eligible patients (N= 12,762) were identified for the melanoma 
and comparison cohorts. After 1: 1 PSM, a total of 8,015 patients were matched 
from each cohort and baseline characteristics were well-balanced. More melanoma 
patients had health care utilizations, including Medicare carrier (99.6% vs. 64.3%), 
Durable Medical Equipment (DME; 19.8% vs. 14.4%) and Home Health Agency 
(HHA; 6.7% vs. 4.1%) claims, outpatient visits (68.4% vs. 35.4%), inpatient (10.9% 
vs. 6.6%) and skilled nursing facility (SNF) stays (2.4% vs. 1.7%), but fewer mela-
noma patients had prescription clams (43.6% vs. 49.8%). Patients diagnosed with 
melanoma incurred higher expenditures, including carrier ($3,527 vs. $1,324), DME 
($153 vs. $101), HHA ($325 vs. $203), outpatient ($8,816 vs. $3,151), inpatient ($1,725 
vs. $1,154) and total health care costs ($15,692 vs. $6,990) (p< 0.0001). Similar SNF, 
hospice and pharmacy claim costs were observed in both cohorts. cOnclusiOns: 
Patients diagnosed with melanoma had a higher burden of illness compared to 
the comparison cohort of non-melanoma patients.
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Objectives: The objective of this cost study was to measure the resource utilisa-
tion and direct costs associated with health care management of cervical abnormal 
cytology and cervical cancer in Slovakia and to provide a basis for cost-effective-
ness evaluations. MethOds: The cross-sectional survey was performed to obtain 
the information on the management of patients with cervical lesions (Low Grade 
Squamous Intraepithelial Lesion (LSIL), High Grade Squamous Intraepithelial Lesion 
(HSIL), Atypical Squamous Cells of Undetermined Significance (ASCUS), Cervical 
Intraepithelial Neoplasia (CIN) I-III) and cervical cancer (clinical stages IA1 to IVB) 
and to estimate the direct costs of the disease management. All types of health care 
used in the management of cervical lesions/cancer were evaluated (diagnostics, 
treatment and follow-up). Average costs per patient were assessed on a yearly basis 
and correspond to the prices in 2013. Results: Concerning the cervical lesions, the 
highest mean annual costs were identified in the CIN III (36.45%; € 1406.62), followed 
by CIN II (27.0%; € 1041.97), the most costly part of health care management being 
the treatment of lesions. The costs of health care management of cervical cancer 
depended on the clinical stage and the frequency of examinations during the year. 
The highest total costs (follow-up included) were identified in the stage III (19.33%; 
€ 4633.35) and IVB (14.24%; € 3413.22). However, the highest mean annual costs of 
diagnostics were determined in stage IB (15.39%; € 542.12), IIA (15.46%; € 544.33), 
IVA and IVB (14.89%; € 524.33). The most expensive treatment (including surgery, 
radiotherapy, concomitant chemoradiotherapy and palliative chemotherapy) was 
identified in the stage IIB (20.89%; € 3616.38) and III (21.01%; € 3637.79). In the most 
advanced stages IVA and IVB, the treatment expenses were lower. Follow-up man-
agement was the most expensive in the stage IVB (15%; € 531.66). cOnclusiOns: 
that their findings can neither be extrapolated to the general patient population 
nor to other points along the pathway. Based on empirical data from a representa-
tive population-based patient cohort, the objective of this study was to develop 
a simulation model that could predict costs at an individual level and estimate 
the real medical costs of treating DLBCL. MethOds: All patients newly diagnosed 
with DLBCL in the UK’s population-based Haematological Malignancy Research 
Network (www.hmrn.org) in 2007 were followed until 2013 (n= 271). The mapped 
treatment pathways, alongside cost information derived from the National Tariff 
2013/14, were incorporated into a patient level simulation model in order to reflect 
the heterogeneities of patient characteristics and treatment options. Results: 
The expected total medical costs were £23,184 for those treated curatively with 
chemotherapy and £2,125 for those with a palliative approach over a period of five 
years. The predicted medical cost of the first line was £15,243, and £16,325 and 
£7,145 for the second line and the third line treatments respectively. The predicted 
costs captured 94% of the actual costs and the proportion of patients simulated in 
each health state was identical to the empirical data, supporting the validity of the 
model. cOnclusiOns: This is the first cost modelling study to use empirical data 
to provide ‘real world’ evidence to estimate medical costs of entire DLBCL treatment 
pathways. Future application of the model developed here could be used to evaluate 
new technologies/treatments and support health care decision makers, especially 
in the era of personalised medicine.
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Objectives: Prevention of chemotherapy-induced nausea and vomiting (CINV) 
remains an important goal for patients receiving cytotoxic treatment. The objec-
tive of this study was to assess, from the Italian National Health Service payer 
perspective, the costs of an antiemetic regimen using aprepitant, a selective neu-
rokinin-1 receptor antagonist, for patients receiving highly emetogenic chemo-
therapy. MethOds: A decision-analytic model was developed to compare an 
aprepitant regimen (aprepitant, ondansetron, and dexamethasone) with a standard 
antiemetic regimen (ondansetron and dexamethasone) for expected costs after 
highly emetogenic chemotherapy. The model was populated with clinical results 
from patients with high-dose cisplatin treatment in a randomized trial of CINV 
preventative therapy. Only direct medical costs (pharmacological treatment and 
emesis) – Euro 2014 – were considered. Sensitivity and Threshold analyses on key 
clinical and economic parameters were performed. Results: Aprepitant regimen 
showed the lower expected treatment cost (aprepitant regimen: € 109.88; standard 
antiemetic regimen € 115.57). The drug acquisition cost of the aprepitant regimen 
(aprepitant regimen: € 86.16; standard antiemetic regimen € 79.37) was offset by 
reduced health care resource utilization costs for CINV (aprepitant regimen: € 23.72; 
standard antiemetic regimen: € 36.20). Sensitivity and Threshold analysis confirmed 
the base case results. cOnclusiOns: The results of this cost-consequence analysis 
suggest that, from the Italian National Health Service payer perspective, aprepi-
tant regimen is a cost-saving strategy compared with antiemetic regimen without 
aprepitant in the prevention of highly emetogenic chemotherapy-induced nausea 
and vomiting.
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Objectives: Evaluate and compare the cost of non-small cell lung cancer (NSCLC) 
treatment by different standards of treatment in Vietnam. MethOds: A tree-deci-
sion model has been developed to estimate the cost of NSCLC. The analysis has 
been conducted based on the perspective of health insurance companies, there-
fore only medical direct costs, including cost for drugs and medical services has 
been evaluated. The list of medical services and drugs was derived from NCCN 
Clinical Practice Guidelines in Oncology (NCCN therapy) and Lung Cancer Therapy 
of Vietnam National Cancer Hospital (Vietnam therapy). The transition rates in the 
model were derived from clinical researches and consultation with experts. The 
cost of drugs and medical services has been averaged from the relevant medical 
services of some major hospitals in Vietnam. Results: The total treatment costs 
increase following the severity of stage whether treatment was implemented by 
Vietnamese or European standards. Moreover, in all stages of disease, the total 
treatment costs of NSCLC by Vietnamese guideline are less than that by NCCN 
standard (74,425,114 vs 79,729,000 in phase I; 139,031,940 vs 210,585,139 in phase II, 
172,333,617 vs 339,542,672 VND in phase III, and 160,690,121 VND vs 266,197,825 VND 
in phase IV, respectively). This can be explained by the lack of some expensive drugs 
and medical services in Vietnam due to the socio-economic conditions of Vietnam. 
In the structure of costs, cost for drugs take the dominant part with approximately 
76.61% by NCCN standard and 74.92% by Vietnamese standard, which is almost 3 
times higher than that of medical services. cOnclusiOns: The high cost of NCSLC 
should be considered to conduct the relevant health care policies, especially with 
high-cost drugs in late stages of disease. The cost of NSCLC treatment by NCCN 
therapy is higher than the cost of NSCLC treatment by Vietnam therapy.
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2039 to EUR 9346, depending on care required, more costly than SREs without hospi-
talization (n= 165). These SREs had median costs of EUR 200 to EUR 1912, depending 
on care required. cOnclusiOns: The impact of SREs on total costs could justify 
policy aimed at actively preventing SREs, e.g. with radionuclide therapy, possibly 
resulting in better quality of life and cost-reduction. Treatment of prostate cancer 
with bone metastases is not very costly compared to lung-and breast cancer with 
similar metastases. However, novel therapeutic options may dramatically increase 
treatment costs in the near future and proper head-to-head cost-effectiveness stud-
ies of all treatment modalities are therefore necessary.
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Objectives: Nowadays breast cancer represents a great economic burden to public 
health care sector in Mexico. This economic burden is due by a lack of prevention 
campaigns and late diagnosis. The analysis aims to estimate the economic impact 
of standard treatment in Mexico for an optimistic scenario of 80% of all breast can-
cer population at early stages compared to the actual distribution (55%) of patients 
along the stages in Mexican setting. MethOds: A hypothetical patient cohort of 8765 
was evaluated; this estimation was obtained from breast cancer 2011 prevalence in 
Mexican population. The analysis was developed in order to estimate average cost 
from the optimistic (base-case) versus actual scenario through public health care 
perspective. Distribution of population in the actual case scenario was 16%, 39%, 
30% and 14% at each stage, I-IV respectively. Direct medical costs were extracted 
from a published source where through a micro-costing technique the cost at each 
stage was obtained. Costs are expressed in 2014 USD ($1USD= $13MXN). It is assumed 
that the economical difference between both scenarios will be used for prevention 
campaigns. Results: The total cost of treatment for all patients on the actual sce-
nario was $124,261,716 compared to $103,549,361 that was the cost calculated at the 
base-case scenario. Economic impact of optimistic scenario is 17% less than total cost 
of treatment at the current scenario. This difference, which represents $20,712,355, 
could be reallocated to diagnose 32,689 more patients at early stages. A sensitivity 
analysis with a best-case scenario was developed considering 100% of the patients 
diagnosed during the first two stages where economic benefits were 314% higher than 
base-case scenario. cOnclusiOns: This analysis suggests that if more public policies 
focused on breast cancer prevention were implemented, then it may lead to a more 
optimal reallocation of resources since direct medical costs increase at late stages.
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Objectives: Prostate cancer is the most common cancer with a current incidence 
of 0,18% among the 2,6million Finnish men. Demand on health care resource use 
is dependent on number of patients needing the service. Patient volumes are 
increasing throughout Europe due to ageing of the population. Despite the sta-
bile or decreasing age-adjusted incidence rates, the absolute number of patients is 
growing. The population characteristics vary within geographical areas, and thus, 
using average parameters for the whole country would lead to biased estimates. 
In this study, burden of prostate cancer cases is estimated on municipality level 
throughout Finland. MethOds: Number of new cancer cases in different hospital 
districts (N= 20) was extracted from the Finnish cancer registry. Official population 
statistics and forecast were used to identify the current and predicted age and sex 
distribution in all of the individual municipalities (N= 320). The data were combined 
with Tableau (8.0) software, where a map-based interface was constructed. This 
was also utilized to visualize the population changes and patient forecasts. Similar 
methodology has been previously utilized in different cancer types. Results: The 
number of new prostate cancer cases each year is estimated to be 1,5-fold by 2040. 
As a case example, a Finnish municipality with 135,000 inhabitants was chosen. 
There were 78 new prostate cancer cases among the 64,332 men in 2011, repre-
senting an incidence of 0,12%. According to our analysis, this university city with 
relatively young population would reach the current country average (0,18%) as 
late as 2040. cOnclusiOns: The disease burden and population demographics are 
unevenly distributed across the country, and thus municipality level estimates are 
needed to inform local decision making and planning. Estimates on the absolute 
number of patients across relevant disease areas are required in order to prepare 
to the challenges health care systems are facing in the future.
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Objectives: Several treatment options are available for 1L NSCLC. In Brazil, patients 
with NSCLC have not been systematically evaluated and different management 
strategies may be associated to different economical outcomes. Therefore, we aimed 
to evaluate the patterns of care and cost of illness of 1L NSCLC treatment according 
to Brazilian supplementary health system. MethOds: Metastatic NSCLC patients 
receiving 1L treatment during year 2013 were eligible and selected from the private 
market administrative claims database (Evidencias database). Treatments, demo-
graphics, supportive drugs and exams were evaluated. Name and any other personal 
identification were not available at the database. The most reported treatments 
according to generic name in 1L therapy were defined as patterns of care. The cost 
of illness was calculated by a bottom-up approach. Exams and associated drugs 
In the management of cervical lesions/cervical cancer, the most expensive are the 
costs of treatment.
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Objectives: To estimate cost-of-illness data associated with treatment of patients 
with stage IIIB/IIIC melanoma with macroscopic lymph node involvement in France, 
Germany and the United Kingdom (UK), whose primary melanoma and regional 
lymph node metastases had been completely resected. MethOds: This retrospec-
tive observational study enrolled patients aged ≥ 18 years, first diagnosed between 1 
January 2009 and 31 December 2011. Data were extracted from medical records and 
via patient survey. Costs were calculated in Euros (€ ) (France, Germany) or pound 
sterling (£) (UK) by collecting resource use and multiplying by country-specific unit 
costs. Costs were estimated from the health care provider perspective. National 
annual costs were estimated from study results and national disease prevalence 
estimates based on European cancer registry and other data. Results: 49 centres 
provided data on 558 patients (55.7% male, 58.2% aged < 65 years at diagnosis, 53.6% 
stage IIIB disease). Mean follow-up was 27 months in France, 26 months in Germany 
and 22 months in the UK. Most patients received no adjuvant treatment in France 
(93.0%) and the UK (97.4%). Use of interferon in Germany was limited (high-dose 
11.0%; intermediate-dose 4.9%; low-dose 15.2%; pegylated 1.8%). Mean total direct 
cost per patient during follow-up was € 23,582 in France, € 32,058 in Germany and 
£31,123 (€ 37,348) in the UK. The largest cost drivers were melanoma treatment 
(mean € 14,004 France, € 21,269 Germany and £24,385 UK) and hospitalisation/emer-
gency treatment (mean € 6,634 France, € 6,950 Germany and £2,827 UK). Total mean 
indirect costs per patient were € 129 in France, € 4,441 in Germany and £1,427 (€ 1,712) 
in the UK. Preliminary estimates for annual national direct cost were € 13.1 million in 
France, € 30.2 million in Germany and £22.8 (€ 27.6) million in the UK. cOnclusiOns: 
The economic burden of stage IIIB/IIIC melanoma with macroscopic lymph node 
involvement was substantial in all three countries. Indirect costs varied by country.
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Objectives: This study estimates the impact of Non-Small Cell Lung Cancer 
(NSCLC) on population health levels and its economic impact in Portugal in 2012.  
MethOds: Data from a cohort of 581 patients with NSCLC completed with an expert 
panel was used to develop a model of cumulated prevalence with a 6 months cycle 
period and a time horizon of 5 years. The impact on health status was measured 
using the Disability Adjusted Life Years (DALYs). The economic impact analysis 
includes two components. The first estimates the direct costs generated by NSCLC 
including consumption of inpatient care and outpatient care (consultations, medi-
cation, diagnostic exams, transportation, etc). The second estimates indirect costs 
related to loss of productivity due to NSCLC. Results: A total of 3,180 deaths in 
Portugal in 2012 were caused by NSCLC, which corresponds to 2.0% of the total 
deaths in Portugal. The DALYs resulting from premature deaths caused by NSCLC 
in 2012 totaled 25,071 representing 4.5% of years lost generated by all deaths in 
the country. For 2012 it is estimated that 3,236 life years were lost due to disability. 
The total disease burden attributable to NSCLC is thus estimated at 28,307 DALY. 
The estimated direct cost generated by NSCLC was € 89 million and that total can 
be broken down into € 32 million for inpatient care and € 57 million for outpatient 
care. The indirect costs must also be taken into account and they added up to € 
54 million. The economic burden of NSCLC is substantial, totaling € 143 million, 
about 0.09% of Portuguese GDP and 0.92% of all Portuguese health spending in 
2012. cOnclusiOns: NSCLC is an important cause of disease burden and costs in 
Portugal and should receive adequate attention from policy makers.
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Objectives: To assess the intramural resource use and associated costs of treating 
patients with prostate cancer, metastatic to the bone, focusing on Skeletal Related 
Events (SREs). Secondary, to quantify the impact of SREs and different treatment 
strategies on total costs. MethOds: A retrospective bottom-up cost of illness study 
performed at a large regional teaching hospital in the Netherlands. Results: A total 
of 136 patients were included, follow-up started at diagnosis of bone metastases and 
stopped at death. The mean total costs were EUR 17.931 per patient (median EUR 
14.039), inpatient days were the most costly category at a mean of EUR 5955 (median 
EUR 3995). SREs that required hospitalization (n= 53) were, at median costs of EUR 
